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Key Points 52 
53 
● EBV type 1 is more prevalent in eBL patients compared to the geographically 54 
matched healthy control group. 55 
● Genome-wide association analysis between cases and controls identifies 6 eBL-56 
associated nonsynonymous variants in EBNA1, EBNA2, BcLF1, and BARF1 57 
genes. 58 
● Analysis of population structure reveals that EBV type 2 exists as two genomic59 
sub groups.60 
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Abstract 61 
Endemic Burkitt lymphoma (eBL), the most prevalent pediatric cancer in sub-Saharan 62 
Africa, is associated with malaria and Epstein Barr virus (EBV). In order to better understand the 63 
role of EBV in eBL, we improved viral DNA enrichment methods and generated a total of 98 64 
new EBV genomes from both eBL cases (N=58) and healthy controls (N=40) residing in the 65 
same geographic region in Kenya. Comparing cases and controls, we found that EBV type 1 66 
was significantly associated with eBL with 74.5% of patients (41/55) versus 47.5% of healthy 67 
children (19/40) carrying type 1 (OR=3.24, 95% CI=1.36 - 7.71, P=0.007). Controlling for EBV 68 
type, we also performed a genome-wide association study identifying 6 nonsynonymous 69 
variants in the genes EBNA1, EBNA2, BcLF1, and BARF1 that were enriched in eBL patients. 70 
Additionally, we observed that viruses isolated from plasma of eBL patients were identical to 71 
their tumor counterpart consistent with circulating viral DNA originating from the tumor. We also 72 
detected three intertypic recombinants carrying type 1 EBNA2 and type 2 EBNA3 regions as 73 
well as one novel genome with a 20 kb deletion resulting in the loss of multiple lytic and virion 74 
genes. Comparing EBV types, genes show differential variation rates as type 1 appears to be 75 
more divergent. Besides, type 2 demonstrates novel substructures. Overall, our findings 76 
address the complexities of EBV population structure and provide new insight into viral 77 
variation, which has the potential to influence eBL oncogenesis.  78 
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Introduction 79 
EBV infects more than 90% of the world's population and typically persists as a chronic 80 
asymptomatic infection.1 While most individuals endure a lifelong infection with minimal effect, 81 
EBV is associated with ~1% of all human malignancies worldwide. EBV was first isolated from 82 
an endemic Burkitt lymphoma (eBL) tumor which is the most prevalent pediatric cancer in sub-83 
Saharan Africa.2 Repeated Plasmodium falciparum infections during childhood appear to drive 84 
this increased incidence.3 Malaria causes polyclonal B-cell expansion and increased expression 85 
of activation-induced cytidine deaminase (AID) dependent DNA damage leading to the hallmark 86 
translocation of the MYC gene under control of the constitutively active immunoglobulin 87 
enhancer.4–6 How EBV potentiates eBL is incompletely understood, however, the clonal 88 
presence of this virus in almost every eBL tumor suggests a necessary role.  89 
EBV strains are categorized into two types based on the high degree of divergence in 90 
the EBNA2 and EBNA3 genes.7–9 This long standing evolutionary division is also present in 91 
orthologous primate viruses,10 yet remains unexplained. While EBV type 1 has been extensively 92 
studied,11,12 because it causes acute infectious mononucleosis and other diseases in the 93 
developed world, type 2 virus studies have not kept pace since infected individuals are less 94 
frequent and found primarily in sub-Saharan Africa. While several recent studies have reported 95 
both types of EBV circulating in western countries,13,14 the African context provides a better 96 
opportunity to examine viral variation because type 1 and type 2 are found in both eBL patients 97 
as well as healthy individuals.8,15,16 Viral variation has been shown to impact differential 98 
transformation and growth, and capacity to block apoptosis or immune recognition.7,17,18 99 
However, studies focusing on only certain genomic regions/proteins potentially miss disease 100 
associations of other loci.19,20 Although new studies have been conducted,21,22 genome-wide 101 
examinations in case-control studies are few and often lack typing the virus.  102 
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To address this shortfall, whole genome sequencing of EBV is now attainable from 103 
tumor, blood, or saliva using targeted viral DNA capture methods.23–28 However, studying EBV 104 
from the blood of healthy individuals remains challenging due to low viral abundance relative to 105 
human DNA (1-10 EBV copy/ng blood DNA). In addition, EBV’s GC-rich genome is inefficiently 106 
amplified using conventional library preparation methods. Here, we present improved methods 107 
for EBV genome enrichment that allow us to sequence virus directly from eBL patients and 108 
healthy children. Leveraging these samples, we sought to define the viral population structure 109 
and characterize viral subtypes collected from children hailing from the same region of western 110 
Kenya. Additionally, we performed the first genome wide association study to identify viral 111 
variants that correlate with eBL pathogenesis.  112 
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Materials and Methods 113 
Ethical approval and sample collection 114 
For this study, we recruited children between 2009 and 2012 with suspected eBL, 115 
between 2-14 years of age, undergoing initial diagnosis at Jaramogi Oginga Odinga Teaching 116 
and Referral Hospital (JOOTRH; Kisumu), which is a regional referral hospital for pediatric 117 
cancer in western Kenya.29 We obtained written informed consent from children’s parents or 118 
legal guardians to enroll them in this study. Ethical approval was obtained from the Institutional 119 
Review Board at the University of Massachusetts Medical School and the Scientific and Ethical 120 
Review Unit at the Kenya Medical Research Institute. For this study, primary tumor biopsies 121 
were collected using fine needle aspirates (FNA) and transferred into RNAlater at the bedside, 122 
prior to induction of chemotherapy. In addition, peripheral blood samples were collected and 123 
fractionated by centrifugation prior to freezing into plasma and cell pellets. All samples were 124 
stored at -80°C prior to nucleic acid extraction.  125 
Improved enrichment of GC-rich EBV in low abundance samples  126 
We used Allprep DNA/RNA/Protein mini kit (Qiagen) for DNA isolations from FNAs and 127 
QIAamp DNA Kit for blood and plasma. We developed an improved multi-step amplification and 128 
enrichment process for the GC-rich EBV genome, particularly in samples with low viral copies. 129 
We used EBV-specific whole genome amplification (sWGA) to provide sufficient material and 130 
targeted enrichment with hybridization probes after the library preparation. For this, we designed 131 
3’-protected oligos following the instructions from Leichty et al.30 (detailed in Supplemental 132 
Methods). For low viral load samples, we added a multiplex long-range PCR amplification 133 
(mlrPCR) step, comprising two sets of non-overlapping EBV-specific primers31 tiling across the 134 
genome. We improved the amplification yield for low copy EBV input (Supplemental Table 1) 135 
by optimizing buffers and reaction conditions (Supplemental Figure 1A and 1B). 136 
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Sequencing library preparation and hybrid capture enrichment 137 
Illumina sequencing library preparation steps consisted of DNA shearing, blunt-end 138 
repair (Quick Blunting kit, NEB), 3'-adenylation (Klenow Fragment 3' to 5' exo-, NEB), and 139 
ligation of indexed sequencing adaptors (Quick Ligation kit, NEB). We PCR amplified libraries to 140 
a final concentration with 10 cycles using KAPA HiFi HotStart ReadyMix and quantified them 141 
using bioanalyzer. We then pooled sample libraries balancing them according to their EBV 142 
content and proceeded to target enrichment hybridization using custom EBV-specific 143 
biotinylated RNA probes (MyBaits, Arbor Biosciences). We sequenced the libraries using 144 
Illumina sequencing instruments with various read lengths ranging from 75bp to 150bp.  145 
Sequence preprocessing and de novo genome assembly 146 
We checked the sequence quality using FastQC (v0.10.1) after trimming residual adapter and 147 
low quality bases (<20) using cutadapt (v1.7.1)32 and prinseq (v0.20.4),33 respectively. After 148 
removing reads that mapped to the human genome (hg38), we de novo assembled the 149 
remaining reads into contigs with VelvetOptimiser (v2.2.5)⁠34 using a kmer search ranging from 150 
21 to 149 to maximize N50. We then ordered and oriented the contigs guided by the reference 151 
using ABACAS, extended with read support using IMAGE,35⁠ and merged the overlapping 152 
contigs to form larger scaffolds (using in-house scripts). By aligning reads back to scaffolds, we 153 
assessed contig quality requiring support from ≥5 unique reads. We created a final genome by 154 
demarcating repetitive and missing regions due to low coverage with sequential ambiguous “N” 155 
nucleotides. We excluded minor variants (<5% of reads) in final assemblies. Deposited 156 
genomes can be accessed from GenBank (accession #) and raw reads can be downloaded 157 
from SRA (SRA accession #).  158 
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Diversity and variant association analysis 159 
We used Mafft (v7.215)36 for multiple sequence alignment (msa) of genomes, and 160 
constructed phylogenetic neighbor-joining trees with Jukes-Cantor substitution model using 161 
MEGA (v6.0).37 We determined variant sites relative to consensus using snp-sites (v2.3.2)38 162 
then projected variant loci on EBV type 1 reference. For principal coordinate analysis (PCoA), 163 
we used dartR (v1.0.5).39 We calculated dN/dS rates per gene using SNAP (v2.1.1) after 164 
excluding frameshift insertions and ambiguous bases.40 For variant association analysis, we 165 
used ‘v-assoc’ function from PSEQ/PLINK. To control for multiple testing, we calculated 166 
empirical p-values with one million permutations (pseq proj v-assoc --phenotype eBL --fix-null --167 
perm 1000000) with EBV type stratification which permutes within types (--strata EBVtype).  168 
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Results 169 
Study participant characteristics 170 
The objective of this study was to examine EBV genetic variation in a region of western 171 
Kenya with a high incidence of eBL29 and determine if any variants are associated with eBL 172 
pathogenesis. We leveraged specimens from eBL patients and healthy children residing in the 173 
same geographic area (Figure 1A).29 We sequenced the virus isolated from 58 eBL cases and 174 
40 healthy Kenyan children, as controls. Patients aging between 1 and 13 years were 175 
predominantly male (74%), consistent with the sex ratio of eBL (Table 1).29 Healthy controls had 176 
similar levels of malaria exposure based on previous epidemiologic studies.41 Control samples 177 
ranged in age from 1 to 6 years. This difference in age was necessary due to the finding that 178 
younger, healthy yet malaria-exposed children have higher average viral loads compared to 179 
older children who have developed immune control over this chronic viral infection.42  180 
Sequencing and assembly quality 181 
EBV is a large GC-rich double stranded DNA virus with 172 kb genome of which ~20% 182 
is repetitive sequence. For the majority of eBL patients, we prepared sequencing libraries 183 
directly from tumor DNA followed by hybrid capture enrichment. For low copy viral samples, 184 
such as eBL plasma and healthy control blood, we designed and implemented additional viral 185 
whole genome amplification and enrichment prior to library preparation and sequencing (Figure 186 
1A; Supplementary Figure 1). We generated a study set of 114 genomes including replicates 187 
from cell lines and primary clinical samples, representing 98 cases and controls. In addition, we 188 
sequenced 20 technical replicates for quality control purposes such as estimation of re-189 
sequencing error or sWGA bias, and sensitivity of detection of mixed infections. The baseline 190 
re-sequencing error rate was limited to ~1.1x10-5 bases when our assemblies are compared 191 
with high-quality known strain genomes43 (Supplemental Table 2). The mean error rate was 192 
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~2.1x10-5 bases for sWGA with GenomiPhi, while it is ~1.1x10-4 bases when we used more 193 
sensitive mlrPCR-sWGA (Methods). We obtained an average of ~5 million reads, resulting in an 194 
average 9,688 depth of coverage across assemblies (Supplemental Table 3). De novo 195 
sequence assembly created large scaffolds covering non-repetitive regions, except three 196 
isolates with low coverage, yielded a median of 137,887bp genomes (ranging 47,534bp - 197 
146,920bp). We determined the types of each isolate by calculating the nucleotide distance to 198 
both reference types in addition to read mapping rates against type-specific regions. Despite our 199 
ability to experimentally detect mixed types at levels as low as 10% (Supplemental Figure 2A), 200 
we found no evidence of mixed infections in our cases and controls. Also, to ensure that our 201 
sample inclusion was unbiased when selecting healthy individuals with high enough viremias to 202 
sequence, we compared the viral loads and found no significant difference between type 1 and 203 
2 (P=0.126, Supplemental Figure 2B).  204 
Equivalence of tumor and plasma viral DNA in eBL cases 205 
The viral genomes from eBL cases included virus reconstructed from plasma and tumor 206 
samples. We confirmed that viral DNA in the plasma was representative of the virus in the tumor 207 
cells by sequencing plasma-tumor pairs from 6 eBL patients (Figure 1B). Accounting for the 208 
sequencing errors, the pairs appeared to be identical. Besides these plasma-tumor pairs, we 209 
further confirmed identical EBV types with additional pairs from 8 separate patients using type-210 
specific PCRs. Overall, these findings demonstrate that viral DNA isolated from plasma 211 
represents the tumor virus. 212 
Structural variation and intertypic recombinants 213 
First, we looked for large deletions within our viral genomes, but did not detect any of the 214 
previously described deletions in EBNAs, even though we were able to detect, as positive 215 
controls, EBNA3C deletion in Raji and the EBNA2 deletion in Daudi cell lines. However, in one 216 
sample we did detect a novel 20kb deletion, spanning from 100 kb to 120 kb in the genome 217 
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(Figure 1C), which contains lytic phase genes BBRF1/2, BBLF1/3, BGLF1/2/3/4/5, and 218 
BDLF2/3/4. Interestingly, none of the latent genes were affected by this deletion.  219 
Next, we interrogated our isolates by comparing the pairwise similarities of each genome 220 
against EBV type 1 and type 2 references. By traversing through the genome with a window, we 221 
were able to delineate regions that were more similar to one type over the other (Figure 1D). As 222 
expected, Jijoye, a type 2 strain, displayed less similarity against type 1 reference around its 223 
EBNA2 and EBNA3 genes, the most divergent region between types, while Namalwa as a type 224 
1 strain shows the same pattern of dissimilarity against type 2 reference around the same 225 
regions. Interestingly, we found three patient-derived genomes, eBL-Tumor-0012, eBL-Tumor-226 
0033, and eBL-Plasma-0049, with mixed similarity trends. Similar to a previously detected 227 
recombinant strain (LN827563.2_sLCL-1.18),43 all of the intertypic isolates carried type 1 228 
EBNA2 and type 2 EBNA3 genes. Although not significant (P=0.268), these new intertypic 229 
hybrids were all isolated from eBL patients while we did not detect any in healthy controls. 230 
Genomic population structure is driven by type differences with distinct 231 
substructure in type 2 viruses.  232 
Our samples present a unique opportunity to study population structure of EBV types 233 
and their co-evolution within a geographically defined region. As expected, the major bifurcation 234 
within the phylogenetic tree based on the entire genome occurs between type 1 and type 2 235 
viruses (Figure 2A). Viruses from eBL patients as well as healthy controls appeared to be 236 
intermixed almost randomly within the type 1 branch. Interestingly, within type 2 genomes 8 237 
eBL-associated isolates formed a sub-cluster. The hybrid genomes clustered with type 2s, 238 
which is consistent with type 2 EBNA3s representing a greater amount of sequence than type 1 239 
EBNA2 region. 240 
We further explored viral population structure with principal coordinate analysis (PCoA) 241 
of variation across the genome. While the first three components cumulatively explain 57.2% of 242 
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the total variance, the first component, which solely accounted for 43.9% of the variance, 243 
separates genomes based on type 1 and type 2 (Figure 2B, upper plot). Similar to the 244 
phylogenetic tree, intertypic genomes positioned more closely to type 2s. Interestingly, the 245 
second and predominantly third components separate type 2 viruses into two distinct clusters, 246 
group A and B (Figure 2B, lower plot). These clusters were reflected, although not as 247 
distinctly, in the structure of the tree as well. The PCoA loading values, which accounts for 248 
37.1% of the variance between the type 2 groups, are predominantly driven by correlated 249 
variation spanning 70kb upstream of EBNA3C (Supplemental Figure 3A and B). Together 250 
these findings suggest that there are two EBV type 2 strains circulating within this population. 251 
We also examined viral variation from the perspective of LMP1. Interestingly, the vast majority 252 
of viruses were grouped into Alaskan and Mediterranean strains (Supplemental Figure 4). For 253 
all available LMP1 type 2 sequences, group A and group B correlated with Mediterranean and 254 
Alaskan, respectively. 255 
EBV type 2 has less diversity compared with type 1 256 
We further explored the pattern and nature of genomic variation across the genome 257 
comparing and contrasting EBV type 1 and type 2. Examining the pairwise divergence of coding 258 
genes for all viral genomes, we found that the divergence was the highest in the type-specific 259 
EBNA genes (EBNA2 and EBNA3s), in particular, with EBNA2 showing the greatest divergence 260 
(d=0.1313 ± 2.3x10-3) (Figure 2C, upper panel). Investigating each type separately, the 261 
diversity within types was low for EBNA2 and EBNA3Cs, consistent with type 1 and 2 being 262 
separated by many fixed differences (Figure 2C, middle panel). In both types, intra-type 263 
divergence was greatest for EBNA1 and LMP1. Most remarkable was the fact that type 2 264 
generally showed lower levels of divergence across the genome (0.0047 ± 3.7x10-3 and 0.0025 265 
± 2.7x10-3 for type 1 and type 2, respectively). Overall, these measures suggest that EBV gene 266 
evolutionary rates differ by types. 267 
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To explore signatures of evolutionary selection, we examined the dN/dS ratios within 268 
coding sequences (Figure 2C, lower panel). Overall most genes showed signals of purifying 269 
selection, as indicated by ω < 1.0, except LMP1, BARF0, and BKRF2 (only type 2). 270 
Interestingly, with dN/dS measures, EBNA2, BSLF1, BSLF2, and BLLF2 genes had relatively 271 
higher rates in type 2 compared to type 1 suggestive of differential evolutionary pressure. 272 
Overall, the magnitude of average nonsynonymous and synonymous changes per gene, 273 
normalized by gene length, reflect the high-level diversity accumulated in certain genes 274 
(Supplemental Figure 5). Latency-associated genes generally have the highest non-275 
synonymous variant rates, but they also have the highest synonymous rates consistent with 276 
longstanding divergence (Figure 2D). Other functional categories, including lytic genes, have 277 
relatively low levels of nonsynonymous mutations suggesting stronger purifying selection.  278 
Global context of Kenyan viruses 279 
To more broadly contextualize our viral population from western Kenya, we examined 280 
the phylogeny of the Kenyan viruses along with other publicly available genomes from across 281 
the world (Supplemental Table 4). Among all isolates, the most polymorphic genomic regions 282 
appeared to be around EBNA2 and EBNA3 genes (Supplemental Figure 6A). Phylogenetic 283 
tree shows that the major types, type 1 and type 2, are the main demarcation point regardless of 284 
the source or geographic location. The three intertypic genomes from our sample set neatly 285 
cluster with the previously isolated intertypic hybrid, sLCL-1.18 (Supplemental Figure 6B). 286 
Type 1 genomes from our study were split into two groups, with one forming a sub-branch only 287 
with Kenyan type 1, including Mutu, Daudi, and several Kenyan LCLs. The second group 288 
interspersed with other African (Ghana, Nigeria, North Africa) and non-African isolates. In 289 
addition, a few of our genomes from healthy carriers clustered with a group of mainly Australian 290 
isolates, however; none of them clustered with South Asian group. Our Kenyan EBV type 2s 291 
generally intermixed with other type 2 genomes.  292 
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Viral Genomic Variants and Associations with eBL 293 
After excluding the intertypic hybrids, we compared type frequencies of EBV genomes 294 
isolated from eBL patients and healthy controls. We observed a significant difference in 295 
frequencies with 74.5% of eBLs carrying type 1 while only 25.5% carried type 2 infections. In 296 
contrast, 47.5% vs. 52.5% of type 1 and type 2, respectively were found in healthy controls. 297 
EBV type 1 was associated with eBL (OR=3.24, 95% CI=1.36 - 7.71, P = 0.007, Fisher’s exact) 298 
(Figure 3A), independent of age and gender (all P>0.05, Supplemental Figure 7). We then 299 
expanded the association analysis to all 2198 non-synonymous single nucleotide variations 300 
across the entire genome (Figure 3B). We did an initial association test for each 301 
nonsynonymous variant and detected 133 significant associations (Supplemental Table 5 & 302 
Methods). The vast majority of these variants were located within the type1-type2 region given 303 
the highly correlated nature of this region. We then stratified by type to detect variation 304 
independent of viral type. This yielded 6 variants solely associated with eBL (Table 2, 305 
Supplemental Table 5). Variant 37668T>C represents a serine residue change to a proline at 306 
the C-terminus of EBNA2 (S485P) which is carried by 24/54 eBL cases; while this variant was 307 
present in only 2/36 healthy controls. Two variants in EBNA1 at 95773A>T and 95778T>G 308 
(N38Y and H39Q, respectively) were both observed in 3/57 eBL isolates while their 309 
corresponding frequencies were 11/36 and 12/37 among healthy controls. 310 
Nucleotide variants in non-coding and promoter regions can affect regulation of viral 311 
gene expression and activity within host cell. BZLF1 is a regulator gene of lytic reactivation and 312 
classified based on its promoter as prototype Zp-P (B95-8) and Zp-V3 (M81 strain).44 We 313 
determined variants at seven positions in the upstream promoter region of BZLF1 314 
(Supplemental Table 6). Interestingly, all of the Kenyan viruses carried C at positions both -525 315 
and -274 (as in Zp-P) regardless of promoter type. We also found that -532 and -524 are 316 
variable in our isolates while these two are not variant in both promoter types. Our results show 317 
that only 12.5% (5/40) type 1 promoter sequences fully resembled Zp-V3 in eBL group as 318 
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opposed to 22% (2/9) healthy genomes, while all of the type 2 genomes, without exception, 319 
carried Zp-V3 type promoter regardless of disease status.   320 
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Discussion 321 
In this study, we investigated genomic diversity of EBV by sampling virus from children 322 
in western Kenya where eBL incidence is high.41 Our improved methods allowed us to 323 
sequence asymptomatically infected healthy controls with relatively low peripheral blood viral 324 
loads, and thereby examine the virus in the population at large.42 We performed the first 325 
association study comparing viral genomes from eBL patients and geographically matched 326 
controls, without the need for viral propagation in LCLs; thus showing that type 1 EBV, as well 327 
as potentially several non-type specific variants, are associated with eBL. Furthermore, as the 328 
first study that characterized significant numbers of EBV type 2, we were able to compare and 329 
contrast both types and explore the viral population, thus discovering novel differences including 330 
population substructure in EBV type 2. 331 
Our sequencing data demonstrated that EBV from plasma is representative of the tumor 332 
virus in eBL patients. This is consistent with the premise that peripheral EBV DNA originates 333 
from apoptotic tumor cells given that cell-free EBV DNA in eBL patients are mostly unprotected 334 
against DNase45, as opposed to being encapsidated during lytic reactivation, and that plasma 335 
EBV levels are associated with tumor burden and stage.46 These findings support the use of 336 
plasma viremia as a surrogate biomarker and the development of plasma-based prognostic 337 
tests with predictive models that could be used during clinical trials.46 The lack of mixed 338 
infections observed in our healthy controls could be due to the limit of detection in blood 339 
compared to virus isolated from saliva.14 Further studies are needed to understand the 340 
coevolution and dynamics of both EBV types. 341 
In addition, we detected three intertypic recombinant EBV genomes solely found within 342 
our eBL patients; similar to those previously described in other cancers.47 It is unclear whether 343 
the intertypic genomes represent a common event with subsequent mutation and recombination 344 
or multiple independent events. If the latter is true, it supports more frequent mixed-type 345 
.CC-BY-NC-ND 4.0 International licensecertified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprint (which was notthis version posted July 2, 2019. . https://doi.org/10.1101/689216doi: bioRxiv preprint 
  17 
infections given that both parents have to be present in the same cell.48–50 It is interesting that all 346 
four intertypics observed to date carry the same type EBNA2/EBNA3 combinations with the type 347 
2 genes being so closely related (Supplemental Figure 8). Thus, if multiple events have 348 
generated these viruses, it suggests that certain strains may have a greater proclivity to 349 
recombine. Further studies will be needed to better define the intertypic population, their origins 350 
and their association with disease.  351 
Importantly, we were able to explore EBV population genetics and compare and contrast 352 
type 1 and type 2 because of their co-prevalence in Africa. As well described, the major 353 
differentiation in terms of genetic variability was the variation correlated with type 1 and type 2 354 
viruses. These viral types showed distinct population characteristics with type 1 harboring 355 
greater diversity especially in functionally important latent genes. Combined with the observed 356 
nucleotide diversity, latency genes appear to have long standing divergence that has 357 
accumulated significant synonymous changes (as opposed to recent sweeps on 358 
nonsynonymous changes that would erase synonymous variants). Global phylogenetic analysis 359 
emphasizes this diversity by providing two main subgroups for type 1 genomes in our 360 
sequencing set. One group represents core local Kenyan viruses while the second group is a 361 
mixture of viruses from across the globe, with the exception of South Asian viruses that group 362 
apart. While previously sequenced type 2 viruses intermingle with western Kenya isolates, the 363 
majority of these originated from East Africa with only a few from West Africa. Interestingly, 364 
intermingling is also true for type 2 as we observed two distinct groups. This is more apparent in 365 
PCA where type 2 virus forms 2 clusters. Examination via PCA, the loading values are 366 
determined by a broad stretch of the genome from the end of EBNA3C to LMP1, where 367 
Mediterranean and Alaskan designations correlate. It remains to be determined whether this 368 
substructure might be due to the introduction of previously geographically isolated viruses or 369 
distinct evolutionary trajectories within the population. Further study is needed with broader 370 
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samplings to understand its significance but our findings suggest that there may be significant 371 
epistasis potentially including LMP1.  372 
By sequencing virus directly from healthy controls, we were able to address the question 373 
of relative tumorigenicity between type 1 and 2. We tested the long-standing hypothesis that 374 
type 1 virus is more strongly associated with eBL, in contrast to type 2. Our work was able to 375 
more definitely answer this question as we were not reliant on LCLs from healthy controls where 376 
type 1 bias in transformation might explain the lack of previous associations. We earlier 377 
demonstrated, by mutational profiling of EBV positive and negative eBL tumors, that the virus, 378 
especially type 1, might mitigate the necessity of certain driver mutations in the host genome.16 In 379 
addition, our genome-wide results controlling for viral type substantiates investigations of non-380 
type associated variation that could also impart oncogenic risk, as we found suggestive trends 381 
for several nonsynonymous variants as well. Only a small subset of type 1 viruses from eBL 382 
patients carried BZLF1 promoter variant, which leads to a gain of function,44 while all type 2 383 
viruses carried this variant suggesting this promoter might be beneficial for type 2 but makes it 384 
unlikely to be a driver of oncogenesis. 385 
Overall, this population-based study provides the groundwork to unravel the complexities 386 
of EBV genome structure and insight into viral variation that influences oncogenesis. Genomic 387 
and mutational analysis of BL tumors identified key differences based on viral content 388 
suggesting new avenues for the development of prognostic molecular biomarkers and the 389 
potential for antiviral therapeutic interventions.  390 
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Tables: 529 
Table 1. Characteristics of children included in EBV sequencing analysis. 530 
 eBL Patients (N=58) 
Healthy Controls 
(N=40) 
Age at collection, 
N (%) 
<6 (yrs) 16 (27.6) 39 (97.5) 
7 - 13 (yrs) 42 (72.4) 1 (2.5) 
Sex, N (%) Female/Male 15/43 (25.9/74.1) 20/20 (50.0/50.0) 
Obtained 
Specimen, N (%) 
Tumor biopsy 41 (41.8) - 
Blood - 40 (100.0) 
Plasma 14 (14.2) - 
New cultured eBL 3 (3.0) - 
 531 
 532 
Table 2. Single nucleotide variants associated with eBL. 533 
Gene Position Ref Alt AA Change 
eBLs Healthy Controls 
P OR 
Genotypes* Alt Count Genotypes* 
Alt 
Count  
EBNA2 37668 T C S485P 54 24 36 2 0.000328 0.1 
EBNA1 95773 A T N38Y 57 3 36 11 0.001322 6.67213 
EBNA1 95778 T G H39Q 57 3 37 12 0.000538 7.16129 
BcLF1 124703 T G K159T 56 1 34 7 0.003178 12.7377 
BcLF1 124709 G A A157V 56 1 34 7 0.003092 12.7377 
BARF1 165131 T C V29A 57 36 36 10 0.004082 0.349462 
Single nucleotide variant association test results with P < 0.01 after type stratification. Table 534 
summarizes the statistically significant single nucleotide variant associations and their effects in the 535 
coding regions. Reference is the genotype based on the consensus of all genomes in the sequencing 536 
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set and variant position denotes the projection to type 1 reference genome (NC_007605). The 537 
association test has been performed for every variant position comparing the frequency of reference 538 
and alternative (minor allele) bases among eBL patient and healthy control children (Fisher’s exact 539 
test). Empirical p values were based on one million permutations. *Genomes with missing data (Ns, 540 
lack of coverage) were excluded. Ref: reference allele, Alt: alternative/variant allele, AA: amino acid, P: 541 
p-value, OR: odds ratio.   542 
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Figure Legends 543 
Figure 1. EBV genome sequencing from tumors and primary clinical samples. 544 
A) Overview of sample collection and methods for sequencing virus from Kenyan children 545 
diagnosed with eBL and healthy children as controls. Hybrid capture was universally performed 546 
along with additional amplification and enrichment steps to overcome low amounts of virus and 547 
input DNA. mlrPCR-sWGA; multiplexed long range PCR - specific whole genome amplification. 548 
B) Comparison of virus from paired tumor (brown circles) and plasma samples (pink circles) at 549 
diagnosis shows viral DNA circulating in the peripheral blood represents the virus in the tumor. 550 
The neighbor-Joining tree is scaled (0.001 substitutions per site) and includes standard 551 
reference genomes for type 1 (NC007605, blue diamond) and type 2 (NC009334, red diamond). 552 
C) The depth of coverage showing an absence of reads from approximately 100 kb to 120 kb is 553 
indicative of a large deletion in the virus from an eBL tumor (top panel). In the middle and lower 554 
panels, although we did not detect any in our tumor or control viruses, we had the power to 555 
detect deletions previously described in tumor lines including EBNA3C deletion in Raji and 556 
ENBA2 deletion in Daudi strains. D) Three intertypic viruses were detected by scanning across 557 
the genomes for percent identity in 1kb windows to both type 1 and type 2 references 558 
(NC_007605, NC_009334, respectively). Top two graphs (grey) represent controls, Jijoye and 559 
Namalwa, followed by 3 intertypic viruses from this study and one publicly available intertypic 560 
virus (LN827563.2_sLCL-1.18 in grey).  561 
Figure 2. Diversity analysis of EBV genomes and coding genes in Kenyan population. 562 
A) Phylogenetic tree of the Western Kenya EBV genomes demonstrating the major type 1 and 563 
type 2 demarcation (blue and red branches, respectively). Pairwise distance calculations were 564 
based on Jukes-Cantor nucleotide substitution model, and the tree was constructed with the 565 
simple Neighbor-Joining method. Genomes are colored based on sample type: healthy children 566 
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blood (green squares), eBL tumors (brown circles), plasma of eBL children (pink circles), and 567 
new and previous cell lines (brown and yellow triangles, respectively). Low coverage genomes 568 
are excluded. B) Principal coordinates analysis plots of nucleotide variations among whole 569 
genome sequences with first and second axes (upper plot, colored by sample type), and second 570 
and third axes (lower plot, colored by EBV subtype and shapes represent case and control). C) 571 
Genetic distance metrics of each EBV gene calculated based on Kimura-2-parameter method 572 
averaged across all genomes (upper panel) or type 1 / type 2 separately (middle panel). Lower 573 
panel shows nonsynonymous to synonymous change (dN/dS) ratios of viral protein coding 574 
genes averaged across all pairwise comparisons with in each group separately. Error bars 575 
represent standard error of mean. (Three intertypic genomes are excluded). D) Average 576 
synonymous and non-synonymous variants in genes are summarized as functional categories 577 
of genes. Variant level represents the number of variants per gene normalized by gene length in 578 
kb. 579 
Figure 3. Significant associations of EBV type 1 genomes and single nucleotide variants 580 
with eBL. 581 
A) The frequency of type 1 and type 2 genomes identified from eBL patients and healthy control 582 
children (excluding the three intertypic hybrid genomes is significantly different (P=0.007, 583 
Fisher’s exact). B) Manhattan plot for genome-wide associations of non-synonymous single 584 
nucleotide variants tested for frequency differences between cases and controls controlling for 585 
type specific variants. The significance of each locus association is represented with an 586 
empirical p-value (negative log10 scale) that was calculated by 1 million permutations with 587 
random label swapping. Permutations were stratified for EBV genome type and adjusted for the 588 
missing genotypes due to lack of coverage. All significant variants associated with eBL cases 589 
are shown in red (P < 0.01). Nucleotide positions are according to type 1 reference genome. 590 
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